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Chicago, IL; 9Northeastern University, Boston, MAA B S T R A C TBackground: Clinical trials often compare hypoglycemic medications
on the basis of glycemic control but do not examine long-term
outcomes (e.g., mortality). This study demonstrates an alternative
approach to lengthening clinical trials to assess these long-term
outcomes. Objective: To use observational quasi-experimental meth-
ods using instrumental variables (IVs) to compare the effect of two
hypoglycemic medications, sulfonylureas (SUs) and thiazolidine-
diones (TZDs), on long-term outcomes. Methods: This study used
administrative data from the Veterans Health Administration and
Medicare from 2000 to 2010. The study population included US
veterans dually enrolled in Medicare who received a prescription for
metformin and then initiated SUs or TZDs. Patients could either
continue on or discontinue metformin after the initiation of the
second agent. Treatment was deﬁned as starting either a SU or a
TZD. Local variations in SU prescribing rates were used as instru-
ments in IV models to control for selection bias. Survival models
predicted all-cause mortality, ambulatory care sensitive conditionee front matter Copyright & 2014, International S
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bu.edu.
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ton, MA 02130.hospitalizations, and stroke or heart attack (acute myocardial infarc-
tion). Results: Starting on SUs compared to TZDs signiﬁcantly
increased the likelihood of experiencing mortality and ACSC hospi-
talization. The estimated hazard ratio for the effect of starting on
SUs compared to TZDs was 1.50 (95% conﬁdence interval [CI] 1.09–
2.09) for all-cause mortality, 1.68 (95% CI 1.31–2.15) for ambulatory
care sensitive condition hospitalization, and 1.15 (95% CI 0.80–1.66)
for acute myocardial infarction or stroke. Conclusions: Our ﬁndings
suggest increased risk of major adverse events associated with SUs
as a second-line agent. Quasi-experimental IV methods may be an
important alternative to lengthening clinical trials to assess long-
term outcomes.
Keywords: comparative effectiveness research, instrumental variables,
provider-prescribing variation, type 2 diabetes.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Diabetes mellitus is the seventh leading cause of death in the
United States and a signiﬁcant cause of morbidity [1]. The
progressive nature of the disease typically requires an escalating
sequence of medications. Choosing the correct medication is
becoming increasingly complex for patients and providers, with
more than 12 classes of glucose-lowering agents currently
approved [2].
There are relatively few comparative effectiveness studies to
guide these medication decisions [2]. Most safety and efﬁcacy
trials focused on comparing medications are based on glycemic
control. These trials require fewer patient-years of follow-up andare less expensive but with a few important exceptions, they do
not provide information on long-term outcomes [2,3]. Trials that
do assess long-term outcomes through posttrial monitoring such
as the United Kingdom Prospective Diabetes Study (UKPDS) or the
Steno-2 study focus on the long-term beneﬁts of intensive
therapy compared with conventional therapy. In posttrial mon-
itoring, attempts are not made to maintain adherence to random-
ized treatments [4,5]. Consequently, there are few systematic
comparisons of long-term outcomes related to speciﬁc medica-
tions, especially beyond ﬁrst-line treatments.
The recent controversy regarding the cardiovascular safety of
thiazolidinediones (TZDs) led the Food and Drug Administration
to release new guidance for the pharmaceutical industry on theociety for Pharmacoeconomics and Outcomes Research (ISPOR).
Economics, VA Boston Healthcare System, 150 South Huntington
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 5 4 – 8 6 2 855need to evaluate the cardiovascular risk of new diabetes medi-
cations. This guidance emphasizes the need for adequately
powered clinical trials that move away from glycemic control as
a surrogate of long-term complications. Instead, clinical trials
should have sufﬁcient cardiovascular events to make accurate
conclusions about the efﬁcacy and safety of the medication [6–8].
The feasibility of conducting such trials has been debated
because time and sample size limitations inhibit the ability of
randomized controlled trials (RCTs) to effectively investigate
long-term outcomes [3,6,7].
Retrospective observational comparative effectiveness studies
are an important complement to RCTs and may be better suited to
measure long-term outcomes [3,9]. The main disadvantage of
observational studies is that the treatment selection could be
inﬂuenced by unmeasured differences in patient risk (selection bias
or confounding by indication). Instrumental variable (IV) models
address selection bias by identifying a factor (the IV) that inﬂuences
treatment but is effectively random with respect to patient risk and
other potential confounders [10,11]. The statistical model isolates
the component of treatment variation attributable to the IV and
measures the relationship between this component and outcomes
[9]. The success of the approach depends on the effective random-
ness of the IV (controlling for all the other variables in the model) as
well as the strength of the IV’s inﬂuence on treatment status [11,12].
This study uses national data from the Veterans Health Admin-
istration (VHA) to demonstrate the value of an IV method in an
observational study when comparing the effectiveness of glycemic
control medications on long-term outcomes. The VHA is the largest
integrated health care system in the United States serving more
than 8.3 million patients each year and spending nearly $4 billion on
prescriptions in 2009 [13,14]. Themanagement of the VHA formulary
provides an ideal setting to use provider-prescribing variation as an
instrument. Starting in 2009, the VHA shifted entirely to a national
formulary. Before this change, there was a national formulary in
addition to formularies at the 21 geographic regions that VHA
services are organized under. Physicians can request approval for
nonformulary drugs, but the ease and timeliness of these requests
vary signiﬁcantly by VHA medical center [14]. Despite these efforts
to standardize drug availability within the VHA, there is signiﬁcant
physician-prescribing practice variation within the VHA [15,16].
VHA patients are randomly assigned to their primary care
physician by variable and often arbitrary methods so this
provider-prescribing variation is unrelated to individual patient
risk [17,18]. Practice pattern variation has been recommended as
an instrument [9,19] and has been used in several previous
studies predicting long-term outcomes including mortality, acute
myocardial infarction (AMI), and ambulatory care sensitive con-
dition (ACSC) hospitalizations [18–21].
In this study, we compared long-term outcomes of the two
most commonly used second-line oral hypoglycemic medications
in the VHA, sulfonylureas (SUs) and TZDs. Current diabetes
treatment guidelines outside the VHA promote metformin (MET)
as the preferred ﬁrst drug but no longer recommend a particular
second-line agent largely because of insufﬁcient evidence on the
long-term outcomes of different medications [1,22,23]. In contrast,
the VHA/Department of Defense clinical treatment guidelines
continue to recommend SUs as the second-line agent [24]. Thus,
it is important to assess the relative impact of these two second-
line agents on long-term outcomes in patients with diabetes to
evaluate recent changes to clinical guidelines outside of the VHA
and to advance VHA formulary policy.
SUs are well-established, inexpensive, and often used as ﬁrst-
and second-line agents in diabetes treatment [25,26]. The use of
SUs increases the risk for hypoglycemia and concerns about their
potential association with cardiovascular disease have been
present since the 1970s [27]. Several recent studies have reported
an increased risk of cardiovascular disease and death amongpatients who started on an SU compared with MET as initial
treatment of diabetes [28,29]. TZDs have also been associated
with adverse events, including cardiovascular outcomes (myo-
cardial infarction and congestive heart failure), osteoporosis, and
bladder cancer [22,30,31].Methods
Data Sources
Patient-level national data from the VHA were used and supple-
mented with data from Medicare to ensure completeness in the
measures of outcomes because VHA patients often use non-VHA
facilities for hospital care [32]. The study was reviewed and
approved by the Institutional Review Board at the VA Boston
Healthcare System.
Study Population
All prescription claims for MET, SU, and TZD between 2000 and
2009 were extracted from VHA pharmacy ﬁles (Fig. 1). Eligible
individuals were prescribed MET before 2008 and then initiated
either SU or TZD between February 1, 2001, and December 31,
2009. Other second-line oral agents were not used frequently
enough in the VHA during the study period to include. Patients
who started insulin after MET were in poorer health than were
individuals who started another oral medication. Consequently,
we assumed that many of these individuals were not appropriate
candidates for oral medications and did not include insulin in the
second-line agent comparisons.
The initiation date of SU or TZD was the start of the study
period (“index date”) for each patient, and the previous 12
months was the baseline period. Clinical guidelines during the
study period recommended annual screening for several key risk
adjustors (e.g., serum creatinine and microalbumin) so we fol-
lowed Prentice et al. [18] and used a 1-year baseline period to
minimize missing data on these risk adjustors [33,34].
To improve comparability between patients, inclusion criteria
attempted to isolate patients at a similar point in the progression
of diabetes. Patients were required to have a MET prescription
during the baseline period before initiating the second drug. To
ensure that all hospitalizations were recorded, we further limited
the cohort to include only those enrolled in Medicare as well as
VHA. The last index date permitted was at the end of 2009 to
allow a minimum 12-month outcome period. Patients were
followed through the end of 2010 until they experienced any of
the outcomes or until they started a third drug. This resulted in a
cohort of 80,936 patients.
Second-Line Treatment
In the VHA, all SUs have always been on the national formulary.
Rosiglitazone was on the national formulary between 2003 and
2007 before safety concerns prompted its removal, and pioglita-
zone has always had nonformulary status [35,36]. Patients who
initiated an SU (n ¼ 73,726) were compared with patients who
started on a TZD (n ¼ 7210). Of individuals who initiated an SU,
47% started on glyburide, 52% started on glipizide, and less than
1% started on other types of SUs including glimepiride. Of
individuals who started on a TZD, 85% started on rosiglitazone
and 15% started on pioglitazone. The large majority of patients
remained on the second-line agent they started. Of the individ-
uals who started on an SU and had at least a 2-year outcome
period, 81% were receiving prescriptions for SUs at least 2 years
later. This number was 64% for those starting on a TZD. Seventy-
ﬁve percent of the patients remained on MET after they initiated
their second drug.
Fig. 1 – Sample selection. MET, metformin; SU, sulfonylurea; TZD, thiazolidinedione; VA, Veterans Affairs. *Baseline is the 12
months before the ﬁrst prescription of the second agent after MET.
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The IV was the proportion of second-line agent prescriptions (SUs or
TZDs) written for SUs by each provider (for all their patients) during
the baseline period. Providers and patients were aligned on the basis
of the index date to minimize confounding that could occur if
patients later switched providers. If a provider had fewer than 10
patient-level second-line agent prescriptions during the baseline
period (70% of the time), the rate at the community-based outpatient
clinic or VHAmedical center where the provider practiced was used.
For ease of presentation, we refer to this provider or facility IV as the
provider-prescribing rate throughout the rest of the article.
Quality Controls
The IV is not effective if correlated with other provider or facility
characteristics that might also affect outcomes, causing biased
estimates of the treatment-outcome relationship. Therefore, we
included three process quality variables: percentage of hemoglo-
bin A1c (Hb A1c) labs greater than or equal to 9% [37,38],
percentage of blood pressure readings greater than or equal to
140/90 mm Hg [39], and percentage of low-density lipoprotein
(LDL) cholesterol labs more than 100 mg/dl [39]. These variables
were computed at the same provider, community-based out-
patient clinic, or VHA medical center level and time periods as
the IV prescribing rate.
Covariates
Additional control variables computed at baseline included
patient age, sex, race, Hb A1c level, serum creatinine, urine
microalbumin, body mass index (see Appendix Table A1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.08.2674 for categorizations), indicator variables for calendar
years corresponding to index dates, 29 indicator variables for
physical and mental health comorbidities using the Elixhauser
algorithm [40], and 8 indicator variables for components of the
Young diabetes severity index [41]. Indicator variables in the
Young diabetes severity index measured retinopathy, nephrop-
athy, neuropathy, cerebrovascular disease, cardiovasculardisease, peripheral vascular disease, and metabolic complica-
tions including ketoacidosis and hyperosmolar and other coma
[41].
Outcomes
Outcomes included all-cause mortality, hospital admission (VHA
or Medicare) for any of 13 ACSCs as deﬁned by the Agency for
Healthcare Research and Quality [42,43], and AMI or stroke. The
VA Vital Status File, which determines the date of death from VA,
Medicare, and Social Security Administration data, was used to
determine all-cause mortality [44]. ACSC hospitalizations are
hypothesized to be preventable with high-quality outpatient care
and include several diabetes and cardiovascular complications
such as uncontrolled diabetes, short and long-term complica-
tions of diabetes, or congestive heart failure [42,43]. AMI deﬁni-
tions were based on Petersen et al. [45] and Kyota et al. [46], and
stroke deﬁnitions were based on Reker et al. [47]. Because of the
overall scarcity of the stroke and AMI outcome in the data,
models that predicted these outcomes separately were unstable.
Consequently, we combined AMI and stroke into one outcome.
The modeled outcome was the amount of time between the
index date and the earliest date of any of the three outcomes,
censoring on the date an individual started a third drug or the
end of the study period in 2010.
Statistical Models
We used STATA Version 10 to estimate the effects of SUs on the
risks of outcomes using Cox proportional hazards models. The IV
approach estimates a pair of simultaneous equations: one for the
likelihood of receiving an SU compared with a TZD and the
second for the likelihood of the outcome. The treatment equation
modeled the likelihood of receiving an SU as a function of the
provider-level prescribing rate and control variables. The out-
come equations related treatment and control variables to
probabilities of death, ACSC hospitalization, and stroke or AMI.
Because the outcome equations were nonlinear, we used the two-
stage residual inclusion technique [48] to estimate IV speciﬁca-
tions. Two-stage models typically require computationally
Table 1 – Selected descriptive demographic,
comorbidity, process quality, and outcome statis-
tics in baseline (n ¼ 80,936).*
Sample characteristics Mean or %
Demographic characteristics
Age (y), mean  SD 69.2  9.1†
Men 79,315 (98)
White 71,545 (88)
Diabetes management
Hb A1c missing 17,297 (21)
Hb A1c o7 25,337 (31)
HbA1c Z7 and Hb A1c o8 22,953 (28)
Hb A1c Z8 and Hb A1c o9 8,547 (11)
Hb A1c Z9 6,802 (8)
Retinopathy complications‡ 11,422 (14)
Nephropathy complications‡ 8,334 (10)
Neuropathy complications‡ 15,896 (20)
Cerebrovascular complications‡ 10,566 (13)
Cardiovascular complications (some)‡ 20,068 (25)
Cardiovascular complications (severe)‡ 20,497 (25)
Peripheral vascular complications‡ 11,198 (14)
Metabolic complications‡ 603 (1)
Cardiovascular comorbidities
BMI missing 18,440 (23)
BMI normal 7,291 (9)
BMI overweight 22,058 (27)
BMI obese 33,147 (41)
Congestive heart failure§ 10,261 (13)
Cardiac arrhythmias§ 17,271 (21)
Valvular disease§ 7,785 (10)
Hypertension§ 67,984 (84)
Pulmonary circulatory disorder§ 1,165 (1)
§
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We bootstrapped standard errors for the all-cause mortality
model and determined that the large samples and strong instru-
ments involved resulted in bootstrapped values that were vir-
tually identical to the asymptotic values generated automatically
by the statistical software.
The Cox models assume that SU treatment increases or
decreases outcome risk by a constant proportion over time. We
tested this assumption using scaled Schoenfeld residuals from
the all-cause mortality and hospitalization equations [50]. Finally,
to control for facility quality differences, we included a facility-
level ﬁxed effect in the treatment equation and a facility-level
random effect in the outcome equations.
Falsiﬁcation Tests
To further conﬁrm the validity of the provider SU prescribing rate
as an instrument, we ran two falsiﬁcation tests. First, we took all
individuals who received a new prescription of MET between 2001
and 2007 and followed them for 1 year. We assumed that these
patients were being treated with MET as their ﬁrst-line agent and
their disease had not progressed to the point of needing a second-
line agent in that time period. Consequently, the SU prescribing
rate should not affect the outcomes in these individuals. We used
provider SU prescribing rates to predict all-cause mortality, ACSC
hospitalization, and stroke or AMI controlling for all the demo-
graphic characteristics, comorbidities, and process quality varia-
bles. Because no individuals in this population were on SUs, all
variables were in the second-stage outcome equation.
Using the same analyses, we used the second falsiﬁcation test
with a sample of individuals who initiated insulin after MET and
took no other diabetes drugs during the study period. Again, we
assumed that SU prescribing rates should not affect the out-
comes in these individuals.Chronic pulmonary disease 18,741 (23)
Provider process quality variables
Provider % Hb A1c 4 ¼ 9 in baseline
period, mean  SD
10  8
Provider BP % 4 ¼ 140 or 4 ¼ 90 in
baseline period, mean  SD
41  10
Provider LDL % 4100 in baseline period,
mean  SD
38  17
Outcomes
ACSC hospitalization 14, 045 (17)
All-cause mortality 7,745 (10)
AMI or stroke 4,291 (5)
ACSC, ambulatory care sensitive condition; AMI, acute myocardial
infarction; BMI, body mass index; BP, blood pressure; Hb A1c,
hemoglobin A1c; LDL, low-density cholesterol.
* For complete descriptive statistics, refer to Appendix Table A1 in
Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.
2014.08.2674.
† Values are n (%) unless indicated otherwise.
‡ Young severity index.
§ Elixhauser comorbidity.Results
Patients in the sample were elderly (mean age 69 years), white
(about 88%), and overwhelmingly male (Table 1). Eight percent of
the patients had average Hb A1c levels of 9 or more and 10% to
20% had diabetes complications such as retinopathy, nephrop-
athy, or neuropathy during the baseline period. Patients also had
high rates of cardiovascular comorbidities, including 41% with
obesity and 25% in both groups of cardiovascular complications
based on the Young diabetes severity index. Ten percent of the
sample died, 17% had an ACSC hospitalization, and 5% experi-
enced a stroke or AMI in the outcome period. The median
number of days between the ﬁrst MET prescription and the ﬁrst
prescription for an SU or a TZD was 637 days (interquartile range
239–1210; data not shown).
The ﬁrst two columns of Table 2 compare means of selected
demographic characteristics and risk adjustment variables focused
on diabetes severity and cardiovascular comorbidities for patients
who started on SUs compared with TZDs. Individuals who started
on an SU were a year younger (69.1 vs. 70.1 years), but there was no
clear pattern of greater comorbidity burden when compared with
TZD initiators. Patients starting on SUs had higher baseline Hb A1c
levels. Noncardiovascular complications were more prevalent in
the TZD group, but cardiovascular complications were similar
between the two groups. Patients starting on TZDs were linked
with providers with slightly higher rates of uncontrolled LDL and
blood pressure. Individuals starting on an SU had higher ACSC
hospitalizations and all-cause mortality rates than did individuals
starting on a TZD. Patients who started on SUs were followed for
an average of 1167 days, and individuals who started on TZDs
were followed for an average of 1033 days.In an RCT, randomization, if performed successfully, ensures
that patient characteristics will be balanced between treatment
and control groups. The same logic applies to an IV study. To
demonstrate the randomizing effect of the provider’s rate of SU
prescribing as an IV, we divided the patients into those linked to
providers with SU prescribing rates above or below the median
(the last two columns of Table 2). Comparing changes from the
ﬁrst two columns to the last two columns, the individual-level
demographic and comorbidity variables and the process quality
variables become closely balanced as patients were categorized
Table 2 – Selected sample means or percentages for patients starting SU or TZD as second agent and patients
assigned to providers with SU prescribing rates above and below the median.*
Sample characteristics Individual treatment SU prescribing providers
Start SU
(n ¼ 73,726)
Start TZD
(n ¼ 7210)
Bottom 50% SU†
(n ¼ 40,453)
Top 50% SU†
(n ¼ 40,483)
Demographic characteristics
Age (y), mean 69.1‡ 70.1 69.2 69.2
Men 98 98 98 98
White 88 89 87 90
Diabetes management
Hb A1c missing 21 27 22 21
Hb A1c o7 31 36 32 31
Hb A1c Z7 and Hb A1c o8 29 24 28 29
Hb A1c Z8 and Hb A1c o9 11 8 10 11
Hb A1c Z9 9 5 8 8
Retinopathy complications§ 14 16 14 14
Nephropathy complications§ 10 12 10 10
Neuropathy complications§ 19 22 19 20
Cerebrovascular complications§ 13 14 13 13
Cardiovascular complications (some)§ 24 28 25 25
Cardiovascular complications (severe)§ 26 23 25 25
Peripheral vascular complications§ 14 16 14 14
Metabolic complications§ 1 1 1 1
Cardiovascular comorbidities
BMI missing 23 22 22 24
BMI normal 9 10 9 9
BMI overweight 27 29 28 27
BMI obese 41 39 41 41
Congestive heart failure|| 13 12 13 13
Cardiac arrhythmias|| 21 21 21 21
Valvular disease|| 10 11 10 9
Hypertension|| 84 84 84 84
Pulmonary circulatory disorder|| 1 1 1 1
Chronic pulmonary disease|| 23 21 23 24
Provider process quality variables
Provider % Hb A1c 4 ¼ 9 in baseline period, mean 10 10 10 10
Provider BP % 4 ¼ 140 or 4 ¼ 90 in baseline period, mean 41 42 41 41
Provider LDL % 4100 in baseline period, mean 38 40 38 38
Outcomes
ACSC hospitalization 18 13 17 18
All-cause mortality 10 7 9 10
Stroke or AMI 5 4 5 5
ACSC, ambulatory care sensitive condition; AMI, acute myocardial infarction; BMI, body mass index; BP, blood pressure; Hb A1c, hemoglobin
A1c; LDL, low-density cholesterol; SU, sulfonylurea; TZD, thiazolidinedione.
* For complete comparisons on all variables included in model, refer to Appendix Table A2 in Supplemental Materials found at http://dx.doi.
org/10.1016/j.jval.2014.08.2674.
† These two columns show descriptive statistics of patients assigned to providers who prescribe an SU below and above the sample median.
‡ For ease of presentation, percentages are presented unless otherwise noted. Refer to Appendix Table A2 in Supplemental Materials found at
http://dx.doi.org/10.1016/j.jval.2014.08.2674 for sample sizes and SDs.
§ Young severity index.
|| Elixhauser comorbidity.
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randomization was successful.
Receipt of SUs was strongly predicted by provider SU prescrib-
ing history in the ﬁrst-stage equation. The coefﬁcient on provider
SU prescribing history was 2.215 (95% conﬁdence interval [CI]
2.098–2.332), and the F statistic of 1374 easily exceeds the stand-
ard threshold for IV strength (F 4 10) [11] (Table 3). Generally,
individuals who had noncardiovascular diabetes complications at
baseline were signiﬁcantly more likely to start on a TZD and
individuals with severe cardiovascular complications were sig-
niﬁcantly more likely to start on an SU. Individuals assigned toproviders with more LDL values greater than 100 were signiﬁ-
cantly more likely to be prescribed an SU than a TZD.
Patients who started on SUs were at a signiﬁcantly increased risk
of experiencing all-cause mortality and ACSC hospitalization than
were individuals who started on TZDs (Table 4). The estimated
hazard ratio for the effect of starting SUs compared with TZDs was
1.50 (95% CI 1.09–2.09) for all-cause mortality, 1.68 (95% CI 1.31–2.15)
for ACSC hospitalization, and 1.15 (95% CI 0.80–1.66) for AMI or stroke.
Provider SU prescribing rates did not have a signiﬁcant effect
on any of the outcomes in either sample used for falsiﬁcation
tests (Table 5). Because neither sample included individuals who
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 5 4 – 8 6 2 859were likely candidates for SUs, this lack of relationship between
SU prescribing rates and outcomes indicates that the only effect
of the IV on the outcome was through its effect on receipt of
treatment, validating the SU prescribing rate as an instrument.Discussion
Using a national sample of veterans diagnosed with diabetes,
who were prescribed a second-line agent after MET, and with up
to 10 years of follow-up, we observed that individuals who
started on SUs compared with TZDs were signiﬁcantly more
likely to die or have an ACSC hospitalization. We found these
effects using an IV statistical model featuring extensive patient
characteristics and provider-level quality of care controls
and exploiting prescribing patterns as a source of quasi-Table 3 – First-stage Probit: Receiving SUs compared wit
Explanatory variables
Instrument
Provider prescribing history
Demographic characteristics
Age
Men
White (reference ¼ black)
Other
Diabetes management
Hb A1c missing (reference ¼ Hb A1c o7)
Hb A1c Z7 & Hb A1c o8
Hb A1c Z8 & Hb A1c o9
Hb A1c Z9
Retinopathy complications†
Nephropathy complications†
Neuropathy complications†
Cerebrovascular complications†
Cardiovascular complications (some)†
Cardiovascular complications (severe)†
Peripheral vascular complications†
Metabolic complications†
Microalbumin missing (reference ¼ microalbumin normal)
Microalbumin high
Serum creatinine missing (reference ¼ serum creatinine normal)
Serum creatinine high
Cardiovascular comorbidities
BMI missing (reference ¼ BMI normal)
BMI overweight
BMI obese
Congestive heart failure‡
Cardiac arrhythmias‡
Valvular disease‡
Hypertension‡
Pulmonary circulatory disorder‡
Chronic pulmonary disease‡
Provider process quality variables
Provider % Hb A1c 4 ¼ 9 in baseline period
Provider BP % 4 ¼ 140 and 4 ¼ 90 in baseline period
Provider LDL% 4100 in baseline period
BMI, body mass index; BP, blood pressure; Hb A1c, hemoglobin A1c; LDL, lo
* Model also includes baseline demographic characteristics, all Elixhaus
Center ﬁxed effects, and year effects that are not shown. Refer to Appen
1016/j.jval.2014.08.2674 for complete results.
† Young severity index.
‡ Elixhauser comorbidity.randomization. Our ﬁndings are consistent with other large
observational studies that have found increased risks for indi-
viduals who start on SUs compared with MET as initial treatment
for type 2 diabetes [28,51].
Older RCTs have not consistently found greater risks for
individuals initiating SUs as a ﬁrst-line agent compared with
other medications. For example, the UKPDS randomized newly
diagnosed individuals to SUs or insulin and found no signiﬁcant
differences in all-cause mortality. A UKPDS subpopulation
focused on patients diagnosed with obesity suggested that
there might be protective effects of MET [52]. The A Diabetes
Outcome Prevent Trial found that individuals who started on
glyburide had lower rates of cardiovascular disease than did
individuals who started on MET or rosiglitazone but there was
no difference between the three drugs in hospitalization or
mortality [53].h TZDs (n ¼ 80,936).*
Coefﬁcient P o|t| 95% conﬁdence interval
2.215 0.000 2.098–2.332
0.002 0.050 0.004 to 0.000
0.103 0.031 0.009–0.197
0.121 0.000 0.176 to 0.067
0.083 0.087 0.177 to 0.012
0.014 0.554 0.061 to 0.033
0.136 0.000 0.100–0.172
0.217 0.000 0.165–0.268
0.326 0.000 0.266–0.385
0.064 0.001 0.102 to 0.026
0.094 0.001 0.147 to 0.040
0.078 0.000 0.112 to 0.043
0.010 0.629 0.052 to 0.031
0.040 0.019 0.074 to 0.007
0.053 0.033 0.004–0.103
0.016 0.441 0.055 to 0.024
0.005 0.946 0.152 to 0.141
0.007 0.694 0.043 to 0.028
0.075 0.065 0.005 to 0.154
0.117 0.000 0.164 to 0.069
0.040 0.138 0.093 to 0.013
0.034 0.223 0.088 to 0.021
0.008 0.768 0.059 to 0.043
0.022 0.398 0.073 to 0.029
0.116 0.000 0.062–0.171
0.009 0.652 0.031 to 0.050
0.022 0.365 0.070 to 0.026
0.026 0.172 0.064 to 0.012
0.036 0.552 0.155 to 0.083
0.058 0.001 0.024–0.092
0.182 0.054 0.366 to 0.003
0.024 0.798 0.210 to 0.161
0.181 0.000 0.085–0.277
w-density cholesterol; SUs, sulfonylureas; TZDs, thiazolidinediones.
er comorbidities, provider quality controls, Veterans Affairs Medical
dix Table A3 in Supplemental Materials found at http://dx.doi.org/10.
Table 4 – Second-stage Cox proportional hazard models: Effect of SUs on mortality, ACSC hospitalization, and
cardiovascular outcomes (n ¼ 80,936).*
Outcomes Hazard ratio P o |t| 95% conﬁdence interval
All-cause mortality 1.50 0.014 1.09–2.09
ACSC hospitalization 1.68 o0.001 1.30–2.15
Stroke or heart attack 1.15 0.457 0.80–1.66
ACSC, ambulatory care sensitive condition; BMI, body mass index; Hb A1c, hemoglobin A1c; SUs, sulfonylureas.
* Models include baseline demographic characteristics, Elixhauser comorbidities, Young severity index, Hb A1c, BMI, microalbumin, serum
creatinine, provider quality controls, year ﬁxed effects, and Veterans Affairs Medical Center random effects. Refer to Appendix Tables A4 to
A6 in Supplemental Materials found at http://dx.doi.org/10.1016/j.jval.2014.08.2674 for complete results.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 5 4 – 8 6 2860The overall purpose and design of RCTs compared with
observational studies may help explain the discrepancy in the
ﬁndings related to the SU risk between the two types of studies.
RCTs are designed to focus on the efﬁcacy of a treatment in a
tightly controlled setting with a homogeneous and small sample
population, often requiring a focus on a limited number of
immediate or short-term outcomes [3]. Meta-analyses have con-
sistently concluded that there is insufﬁcient evidence on long-
term outcomes when comparing hypoglycemic medications
[1,22].
Acknowledging this lack of data, recent Food and Drug
Administration guidance strongly encourages clinical trials of
diabetes medications to include adequate patient populations at
high risk of cardiovascular outcomes [6–8] but this may be
difﬁcult to do. As overall medical care improves, event rates
decline in the overall population. An analysis of event rates by
Preiss et al. [7] of past trials that excluded patients with a history
of cardiovascular disease or proteinurea concluded that future
trials would require colossal participant numbers to achieve
adequately powered results based on mortality and cardiovascu-
lar event rates [7]. Consequently, clinical trials that recruit
enough patients to adequately observe rare long-term outcomes,
such as stroke, will be lengthy and costly [2]. The cost is so high
that some researchers have suggested that regulatory agencies
need to change the patent regulations (e.g., lengthen patent
protection) to encourage pharmaceutical companies to invest in
new medications and clinical trials [6,54]. Focusing trials on
patients who are at the highest risk for experiencing cardiovas-
cular disease is also problematic because the disease may be too
far advanced to be effectively modiﬁed. Also, there are greater
ethical considerations to enrolling higher risk patients who may
not tolerate adverse effects as well [6].
Observational studies can provide complementary data to
clinical trial evidence that does not exist or is difﬁcult to obtain.
The larger sample sizes of observational studies are well suited to
assess the effectiveness of treatments in real-world clinicalTable 5 – Falsiﬁcation test: Effect of SU prescribing rate o
outcomes.*
Outcomes Hazard ratio
MET-only sample (n ¼ 76,860)
All-cause mortality 1.30
ACSC hospitalization 1.23
Stroke or heart attack 1.11
MET and insulin sample (n ¼ 4015)
Mortality 1.30
ACSC hospitalization† 0.81
ACSC, ambulatory care sensitive condition; BMI, body mass index; Hb A
* Models include baseline demographic characteristics, Elixhauser como
creatinine, provider quality controls, year ﬁxed effects, and Veterans A
† The stroke and heart attack model did not converge in the MET and insettings with a more heterogeneous population in less tightly
controlled conditions [3]. For example, this study had 80,936
patients compared with 4209 randomized patients in the UKPDS
trial and 4351 in the A Diabetes Outcome Prevent Trial [4,53]. The
key to capitalizing on the power of observational data is to
account for selection bias or confounding by indication. This
study follows the methodology of several previous studies by
using provider-prescribing variation as an IV to minimize this
risk of confounding [18–21,55]. Similar to the ﬁndings of these
studies, physician-prescribing variation was unrelated to an
individual patient’s risk factors (Table 2) and signiﬁcantly asso-
ciated with treatment selection (Table 3) [18,19]. Physician-
prescribing variation is valid as an IV if it inﬂuences outcomes
only through treatment selection (e.g., SUs compared with TZDs).
Another strength of this study is that we included several
previously tested measures of provider process quality controls
to help ensure that the IV inﬂuences outcomes only through
treatment [18]. These relatively new methods in biomedical
research would be accepted more quickly if they could be further
validated against RCTs with long-term outcomes. Some of this
has been done [55,56], but each research question involves
different potential confounders and few clinical trials have the
long-term outcome data required to validate these methods.
This study has several limitations. It included several controls
for provider quality and facility effects, but quality has many
dimensions and we could not explicitly control for them all.
Consequently, it is possible that some uncontrolled provider
quality variable was responsible for the results. However, to
account for the measured effect of SU, an omitted quality factor
would have to be highly correlated with SU prescribing and
uncorrelated with LDL control, blood pressure control, Hb A1c
control, or facility effects. This seems unlikely. It is also impor-
tant to note that in this study SU and TZD use was compared
relative to each other. Although TZD use was associated with
fewer adverse outcomes than was SU use, this does not inform
the relative safety proﬁle of SUs and TZDs in comparison to othern mortality, ACSC hospitalization, and cardiovascular
P o |t| 95% conﬁdence Interval
0.115 0.94–1.79
0.149 0.93–1.62
0.657 0.70–1.77
0.427 0.68–2.52
0.425 0.47–1.37
1c, hemoglobin A1c; MET, metformin; SU, sulfonylurea.
rbidities, Young severity index, Hb A1c, BMI, microalbumin, serum
ffairs Medical Center random effects.
sulin sample because of small sample sizes.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 8 5 4 – 8 6 2 861newer agents, such as dipeptidyl peptidase-4 inhibitors. Finally,
another limitation is that the study population was nearly all
male and low-income veterans. Future research should continue
to compare the long-term outcomes of SUs and TZDs in popula-
tions not well represented in our sample.
Our study found that individuals who used an SU as a second-
line agent experienced signiﬁcantly more adverse long-term
health outcomes than did individuals who started on a TZD.
Given the proliferation of new treatments for type 2 diabetes,
quasi-experimental IV methods may be useful to assess long-
term outcomes in a more timely and cost-effective manner than
conducting long RCTs.Acknowledgments
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